

Trulicity[®] (dulaglutide) – New indication

- On February 21, 2020, <u>Eli Lilly announced</u> the FDA approval of <u>Trulicty (dulaglutide)</u>, to reduce the
 risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial
 infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus (T2DM) who have established
 cardiovascular (CV) disease or multiple CV risk factors.
 - Trulicty has not been studied in patients with a history of pancreatitis. Other antidiabetic therapies should be considered in patients with a history of pancreatitis.
 - Trulicity should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Trulicity is not a substitute for insulin.
 - Trulicity has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of Trulicity is not recommended in patients with pre-existing severe gastrointestinal disease.
- Trulicty is also approved as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.
- The approval of Trulicity for the new indication was based on the REWIND study, a randomized, placebo-controlled, double-blind study in 9,901 adult patients with T2DM and established CV disease or multiple CV risk factors. Patients were randomized to Trulicity or placebo. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component MACE outcome, which included CV death, non-fatal myocardial infarction, and non-fatal stroke.
 - Compared with placebo, Trulicity significantly reduced the risk of first occurrence of primary composite endpoint (12.0% vs. 13.4%; hazard ratio: 0.88; 95% CI: 0.79, 0.99; p = 0.26).
- Trulicty carries a boxed warning for risk of thyroid C-cell tumors.
- The recommended initial dose of Trulicty in all patients is 0.75 mg subcutaneously once weekly. The
 dose may be increased to 1.5 mg once weekly for additional glycemic control. The maximum
 recommended dose is 1.5 mg once weekly.
- Trulicty should be injected in the abdomen, thigh, or upper arm.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.